CAR t therapy takes on lupus, MS, and more in first human safety trial
NCT ID NCT07085676
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in 120 adults aged 18 to 80. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-SYNTHETASE SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hadassah MO
RECRUITINGJerusalem, 9574869, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin biopsies unlock new treatments for scleroderma?
- Could a skin patch ease stomach pain in scleroderma?
- Could a painless microneedle pad ease Raynaud's in scleroderma?
- Can tracking daily life unlock myasthenia gravis mysteries?
- Could a simple blood test flag heart risk in rheumatoid arthritis?
- Learning to Self-Care: a new approach to ease RA stiffness?